Cognitive-behavioral therapies are being combined with psychedelic substances such as ketamine, psilocybin, and MDMA to treat mental disorders, but the way they are integrated varies widely across studies. A systematic review of 9 clinical trials involving 283 patients found that traditional cognitive behavioral therapy was the most common approach, used in 6 studies, while mindfulness-based cognitive therapy and acceptance and commitment therapy were each used in 2 and 1 studies respectively. The timing of therapy relative to the psychedelic experience—before, during, or after—also differed. The findings highlight the need for more consistent research to clarify how these therapeutic models are best implemented.
Adults with major depressive disorder who report higher levels of dispositional mindfulness—the tendency to attend to present-moment experiences with openness and awareness—show fewer depressive and anxiety symptoms, better sleep quality, and higher self-esteem compared to those with lower trait mindfulness. In a cross-sectional study of 97 adults diagnosed with MDD, two clusters emerged: a High Trait group and a Low Trait group. The High Trait group had significantly lower depressive symptoms (d = 0.795) and anxiety symptoms (d = 0.739), and higher self-esteem (d = -0.586) and sleep quality (d = 0.460). These results suggest trait mindfulness may protect against poor mental health in depression.
Ketamine rapidly reduces depression symptoms in treatment-resistant depression, but its effects may be enhanced by combining it with psychotherapy. The drug induces neuroplasticity and psychological openness, which could help patients process emotions, restructure thoughts, and maintain improvements. However, research has not yet thoroughly examined whether adding structured psychotherapy to ketamine treatment provides additional benefits.